US › Healthcare

Moleculin Biotech Inc (MBRX)

US · Healthcare · Biotechnology

$0.41-3.67%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-12.8M
Profit YoY
-99.6%
EPS
$-3.54
EPS estimate
$-1.66

EPS came in at -3.54 against a street estimate of -1.66 — a miss of 113.3%.

Key statistics

Market cap
$2.8M
Forward P/E
0.0
P/B
0.18
Book value
$2.85
EPS (TTM)
$-16.16
52-week high
$18.25
52-week low
$0.16
50-day MA
$2.43
200-day MA
$4.46
Beta
1.75

Analyst view

Analysts rate Moleculin Biotech Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $21.00.

Shareholding

Insiders
0.64%
Institutions
3.33%

Largest institutional holders

FundStake
Sabby Management LLC1.06%
Geode Capital Management, LLC0.46%
Vanguard Capital Management, LLC0.20%
HRT FINANCIAL LLC0.19%
Vanguard Fiduciary Trust Co0.09%
Rockefeller Capital Management L.P.0.06%
UBS Group AG0.05%
Tower Research Capital LLC0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Moleculin Biotech Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.